Inhibition of STAT3 activity is well-known to enhance chemosensitivity of multiple tumor types to a number of different cytotoxic agents or other targeted agents; therefore multiple combinations of target inhibition of key pathways for ES like RING1B and STAT3 together with conventional chemotherapy could represent a novel approach for ES patients. This evidence concerns the gene RNF2 and neoplasm.